Medical AI

New long-term data for UPLIZNA and TAVNEOS show sustained disease control and reduced steroid use, offering a tangible difference for rare disease patients.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

MiniMed and Abbott are partnering on a dual glucose-ketone sensor, a move that could shift diabetes care from crisis management to proactive DKA prevention.

A new report shows California's self-insured employers face a puzzling trend: workers' comp claims are at a 5-year low, yet costs are surging. Why?

A fivefold increase in one year, THINK Surgical’s miniature robot is reshaping orthopedics with its unique open platform and powerful industry partnerships.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

A new partnership between TD2 Oncology and Panome Bio aims to merge clinical expertise with deep multi-omics data to accelerate personalized cancer therapies.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

Ionetix wins FDA approval for its generic prostate cancer imaging agent, a move set to boost access and shake up the competitive radiopharmaceutical market.

With new funding from Bregal Sagemount, LSPedia is set to advance its AI tools, moving beyond compliance to build a smarter, safer pharma supply chain.

Following its X3D acquisition, Catalyst MedTech unveils an expanded portfolio and a new strategy to tackle aging equipment and modernize nuclear medicine.

ValGenesis's upcoming event explores AI's pivotal role in pharma validation, charting a course from digital systems to intelligent, compliant operations.

DePuy Synthes acquires novel radiofrequency tracking to move beyond the line-of-sight limits and invasive pins of current robotic joint surgery systems.

A new report reveals Europe's medically-focused cannabis market is finally waking, creating a new global blueprint but also intense competition and price wars.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

A landmark Novo Nordisk study finds 2 in 5 heart patients have hidden inflammation, a major risk for heart attack and stroke despite standard treatments.

With game-changing Phase III data for iza-bren in breast cancer and a deep pipeline, SystImmune is poised to make a major impact at ASCO 2026.

Gene Solutions' AI-driven multi-omics liquid biopsy platform makes waves at a major oncology conference, finding a ready market in Taiwan.

At SLAS 2026, MGI Tech unveiled intelligent platforms for proteomics and clinical automation, signaling a major push to accelerate scientific discovery.

With new CEO Andrew Zeringue, Theromics aims to tackle cancer recurrence with its HeatSYNC gel, a novel approach in the booming ablation market.